COMMUNIQUÉS West-GlobeNewswire

Cellectis publie ses résultats financiers du quatrième trimestre 2024 et de l’exercice 2024 et une mise à jour de ses activités
13/03/2025
○ UCART22 : présentation des données de Phase 1 et de la stratégie de développement prévues au troisième trimestre 2025. Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la [...]
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
13/03/2025
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the [...]
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
13/03/2025
MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2024. Key [...]
Voting Rights and Shares Capital of the Company
13/03/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 13, 2025 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
13/03/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 mars 2025 (GLOBE NEWSWIRE) -- Paris, France, le 13 mars 2025 Place de cotation : [...]
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
13/03/2025
MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of [...]
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
13/03/2025
PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and [...]
MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)
13/03/2025
TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Mother Labs [...]
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
13/03/2025
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
13/03/2025
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive final data from [...]
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
13/03/2025
Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company focused on [...]
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
13/03/2025
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
13/03/2025
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable [...]
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
13/03/2025
Conference Call and Live Audio Webcast Scheduled for March 20, 2025 PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates [...]
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
13/03/2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million [...]
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
13/03/2025
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs [...]
The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results
13/03/2025
- Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE [...]
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
13/03/2025
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining [...]
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
13/03/2025
Q4 2024 revenue increased 24.6% over Q3 2024 ; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 [...]

Pages